drugset / Trial / NCT01979445

Cangrelor to Clopidogrel or Prasugrel Transition Study

NCT01979445

Phase 2 Completed 15 enrolled The Medicines Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

There are two separate objectives in this study: 1. To demonstrate the pharmacodynamic (PD) profile when participants treated with cangrelor are switched to oral prasugrel 60 mg administered 30 minutes (min) after cangrelor infusion is discontinued 2. To demonstrate the PD profile when participants treated with cangrelor are switched to oral clopidogrel 600 mg administered during or immediately after cangrelor infusion.

Timeline

Start
2013-12-02
Primary completion
2014-01-20
Completion
2014-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Cangrelor Small molecule 4 ug/kg Intravenous
Subject Clopidogrel Small molecule 600 mg Oral
Subject Prasugrel Small molecule 60 mg Oral